Skip to content

Just another WordPress site

Douglas Pharmaceutical’s Chief Scientific Officer talks about a new drug for treatment resistant depression

Published 28 May 2019By ysdouglassuperuser

Categorized as Large Dispensers

Leave a comment Cancel reply

You must be logged in to post a comment.

Post navigation

Previous post

Douglas Pharmaceuticals begins work on $35MM Research and Development building

Next post

Douglas wins Best Large Business in the New Zealand International Business Awards

Search

Recent Posts

Douglas Fiji receives a Recognition Award for Outstanding Achievement at the Prime Minister’s International Business Awards
Douglas Pharmaceuticals expands its Contract Development and Manufacturing (CDMO) business
Douglas Pharmaceuticals secures US licensing deal to treat high grade cervical dysplasia
Feeding people, not landfill
Douglas Innovation awarded Excellence at the Property Council NZ Awards

Recent Comments

No comments to show.

Archives

December 2023
October 2023
September 2023
August 2023
July 2023
April 2023
February 2023
October 2022
September 2022
June 2021
April 2020
November 2019
May 2019
April 2019
January 2019
December 2018
November 2018

Categories

Awards
Commercial
Corporate Responsibility
Large Dispensers
Manufacturing
Research

Douglas API

Proudly powered by WordPress.